Stuttgart - Delayed Quote EUR

Clinuvel Pharmaceuticals Ltd (UR9.SG)

6.86

+0.05

+(0.73%)

At close: January 10 at 8:11:15 AM GMT+1

Exploring 3 High Growth Tech Stocks In Australia

The Australian market is experiencing a cautious start to the year, with the ASX 200 expected to open slightly lower amid global uncertainties and a weakening Aussie dollar, reflecting broader concerns about economic data and interest rate projections. In this environment, identifying high-growth tech stocks requires careful consideration of factors such as innovative potential and resilience in fluctuating market conditions.

Simply Wall St. 8 days ago

MEOBF

MESO

CLVLF
0.00%
ASX Growth Stocks With Strong Insider Confidence

As the Australian stock market closes on a positive note with a modest gain in the ASX 200, investors are digesting the Reserve Bank of Australia's recent minutes that highlight persistent inflation concerns. In this environment, growth companies with high insider ownership can be particularly appealing as they often signal strong internal confidence and alignment with shareholder interests.

Simply Wall St. 17 days ago

GYG.AX

CLVLF
0.00%
CLVLY
-0.43%
Exploring High Growth Tech Stocks in Australia December 2024

As the Australian market experiences a modest uptick with the ASX200 rising by 0.3% to 8,488 points, the IT sector stands out as a strong performer, climbing by 1.1%, amidst broader economic indicators suggesting potential volatility and constraints in the coming year. In this environment, identifying high-growth tech stocks requires careful consideration of their ability to thrive in dynamic conditions and leverage technological advancements to sustain momentum within an evolving market...

Simply Wall St. last month

MEOBF

MESO

FNCHF
ASX Growth Companies With High Insider Ownership For November 2024

In the midst of a challenging trading session, the ASX200 closed down 0.7% at 8,359 points, largely impacted by a sell-off in energy stocks and banks following tariff threats from Donald Trump. Despite these headwinds, certain sectors like Staples and Information Technology showed resilience, highlighting the importance of strategic stock selection—particularly companies with strong growth potential and high insider ownership that can offer stability and confidence to investors during...

Simply Wall St. last month

AXGLF

ABB.AX

CLVLF
0.00%
Three High Growth Tech Stocks in Australia

As the Australian market experiences a modest uptick with the ASX200 rising around 1% to 8,210 points, investors are closely monitoring the ongoing US election and its potential impact on global markets. In this environment of cautious optimism, identifying high growth tech stocks requires careful consideration of factors such as innovation potential, market positioning, and adaptability in dynamic sectors like technology.

Simply Wall St. 2 months ago

CLVLF
0.00%
CLVLY
-0.43%
MEOBF
ASX Growth Leaders Featuring Clinuvel Pharmaceuticals And 2 Insider-Favored Stocks

As the Australian market holds steady with investors eyeing key inflation data and recent movements in major indices, the focus turns to growth companies showing resilience amidst economic fluctuations. In this environment, stocks with high insider ownership can be particularly appealing as they often indicate confidence from those closest to the company's operations.

Simply Wall St. 2 months ago

CLVLF
0.00%
CLVLY
-0.43%
LTSRF
Clinuvel Pharmaceuticals Ltd (CLVLF) (Q4 2024) Earnings Call Highlights: Record Revenue and ...

Clinuvel Pharmaceuticals Ltd (CLVLF) reports robust financial growth with a 15% revenue increase and outlines future expansion plans amidst rising expenses.

GuruFocus.com 3 months ago

CUV.AX
+0.70%
High Growth Tech Stocks In Australia Featuring 3 Promising Picks

Over the last 7 days, the Australian market has risen by 1.1%, contributing to an impressive 18% increase over the past year, with earnings forecasted to grow by 12% annually. In this thriving environment, identifying high growth tech stocks involves looking for companies that demonstrate strong innovation and scalability potential to capitalize on these favorable market conditions.

Simply Wall St. 3 months ago

CLVLF
0.00%
CLVLY
-0.43%
PMCUF
CLINUVEL files Canadian New Drug Submission for SCENESSE® in EPP

Patient Special Access Program continues during Health Canada reviewMELBOURNE, Australia, Oct. 01, 2024 (GLOBE NEWSWIRE) -- CLINUVEL has filed a New Drug Submission (NDS) to Health Canada, seeking approval for its novel photoprotective therapy SCENESSE® (afamelanotide) for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP). If approved, SCENESSE® would be the first treatment for Canadian EPP patients. Health Canada review process Health Canada’s Health Pro

GlobeNewswire 3 months ago

CLVLF
0.00%
CLVLY
-0.43%
3 ASX Growth Companies With Insider Ownership Up To 22%

The Australian market is on the cusp of another record high, buoyed by strong performances in global indices and robust commodity prices, particularly in iron ore and precious metals. In this thriving environment, identifying growth companies with significant insider ownership can be a strategic move for investors looking to align with those who have a vested interest in their company's success.

Simply Wall St. 3 months ago

CLVLF
0.00%
CLVLY
-0.43%
VTEXF
Clinuvel Pharmaceuticals (ASX:CUV) Posted Healthy Earnings But There Are Some Other Factors To Be Aware Of

Unsurprisingly, Clinuvel Pharmaceuticals Limited's ( ASX:CUV ) stock price was strong on the back of its healthy...

Simply Wall St. 3 months ago

CLVLF
0.00%
CLVLY
-0.43%
High Growth Tech Stocks in Australia Featuring Three Promising Companies

Over the last 7 days, the Australian market has remained flat with a notable 3.6% gain in the Financials sector, and it is up 10% over the past year with earnings forecasted to grow by 12% annually. In this context, identifying high growth tech stocks that align with these positive market conditions can be crucial for investors looking to capitalize on robust earnings potential and sector-specific momentum.

Simply Wall St. 4 months ago

CLVLF
0.00%
CLVLY
-0.43%
PMCUF
Clinuvel Pharmaceuticals Full Year 2024 Earnings: Beats Expectations

Clinuvel Pharmaceuticals ( ASX:CUV ) Full Year 2024 Results Key Financial Results Revenue: AU$88.2m (up 13% from FY...

Simply Wall St. 4 months ago

CLVLF
0.00%
CLVLY
-0.43%
Discover Clinuvel Pharmaceuticals And 2 Other High Growth Stocks On The ASX

In the last week, the Australian market has been flat, but over the past 12 months, it has risen by 10.0%, with earnings expected to grow by 12% per annum in the coming years. In this context, high-growth companies with significant insider ownership can be particularly attractive as they often signal strong confidence from those closest to the business.

Simply Wall St. 4 months ago

NNCSF

CLVLF
0.00%
CLVLY
-0.43%
Exploring Three High Growth Tech Stocks in Australia

The Australian market has seen a mix of performances recently, with the ASX200 breaking its winning streak and closing slightly down by 0.04% at 8,024 points. Amidst these fluctuations, sectors such as Telecommunication and Health Care have shown resilience, rising by 0.6%, while Utilities and Energy saw declines. In this environment of mixed sector performance, identifying high-growth tech stocks requires a keen understanding of market dynamics and the ability to spot companies with robust...

Simply Wall St. 4 months ago

CLVLF
0.00%
CLVLY
-0.43%
DUGTF
Clinuvel Pharmaceuticals Leads Three High Growth Companies With Significant Insider Ownership

As global markets navigate through a period of relative calm with anticipation for upcoming earnings reports and key economic indicators, investors continue to assess the landscape for robust investment opportunities. In this environment, growth companies with high insider ownership can be particularly compelling, as substantial insider stakes often signal confidence in the company's future prospects from those who know it best.

Simply Wall St. 6 months ago

CLVLF
0.00%
CLVLY
-0.43%
EXNWF
Afamelanotide in fair-skinned Parkinson’s patients

Preclinical models show benefit of afamelanotide as MC1R therapy in Parkinson’s DiseaseMELBOURNE, Australia, June 18, 2024 (GLOBE NEWSWIRE) -- CLINUVEL today announced a novel clinical program evaluating afamelanotide as a treatment in early-stage Parkinson’s Disease (PD or Parkinson’s) in fair-skinned patients. The program objectives are to determine whether afamelanotide – through melanocortin-1 receptor (MC1R) activation – is able to lower α-synuclein (a toxin) in blood levels in PD patients,

GlobeNewswire 6 months ago

CLVLF
0.00%
CLVLY
-0.43%
Institutions own 21% of Clinuvel Pharmaceuticals Limited (ASX:CUV) shares but retail investors control 59% of the company

Key Insights The considerable ownership by retail investors in Clinuvel Pharmaceuticals indicates that they...

Simply Wall St. 7 months ago

CLVLF
0.00%
CLVLY
-0.43%
Is Clinuvel Pharmaceuticals Limited's (ASX:CUV) Stock's Recent Performance Being Led By Its Attractive Financial Prospects?

Clinuvel Pharmaceuticals' (ASX:CUV) stock is up by a considerable 8.7% over the past month. Since the market usually...

Simply Wall St. 8 months ago

CLVLF
0.00%
CLVLY
-0.43%
Photomedicine Pioneer CLINUVEL Unveils Clinical, Cosmetic Ambitions to German Investors

DÜSSELDORF, Germany, March 28, 2024 (GLOBE NEWSWIRE) -- Pioneering biopharmaceutical company CLINUVEL yesterday hosted a wide-ranging market briefing discussing its novel drug SCENESSE® (afamelanotide) and the future of photomedicine. Over 70 guests discussed the Company’s unique history and future growth potential at an invitation-only event in Düsseldorf. Managing Director and CEO, Dr Philippe Wolgen shared the Company’s success in establishing profitability over the past seven financial years

GlobeNewswire 9 months ago

CLVLF
0.00%
CLVLY
-0.43%

Performance Overview

Return	UR9.SG	S&P/ASX 200 [XJO]
YTD	-3.51%	+1.65%
1-Year	-30.27%	+11.05%
3-Year	-59.57%	+11.37%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Clinuvel Pharmaceuticals Ltd (UR9.SG)

Exploring 3 High Growth Tech Stocks In Australia

ASX Growth Stocks With Strong Insider Confidence

Exploring High Growth Tech Stocks in Australia December 2024

ASX Growth Companies With High Insider Ownership For November 2024

Three High Growth Tech Stocks in Australia

ASX Growth Leaders Featuring Clinuvel Pharmaceuticals And 2 Insider-Favored Stocks

Clinuvel Pharmaceuticals Ltd (CLVLF) (Q4 2024) Earnings Call Highlights: Record Revenue and ...

High Growth Tech Stocks In Australia Featuring 3 Promising Picks

CLINUVEL files Canadian New Drug Submission for SCENESSE® in EPP

3 ASX Growth Companies With Insider Ownership Up To 22%

Clinuvel Pharmaceuticals (ASX:CUV) Posted Healthy Earnings But There Are Some Other Factors To Be Aware Of

High Growth Tech Stocks in Australia Featuring Three Promising Companies

Clinuvel Pharmaceuticals Full Year 2024 Earnings: Beats Expectations

Discover Clinuvel Pharmaceuticals And 2 Other High Growth Stocks On The ASX

Exploring Three High Growth Tech Stocks in Australia

Clinuvel Pharmaceuticals Leads Three High Growth Companies With Significant Insider Ownership

Afamelanotide in fair-skinned Parkinson’s patients

Institutions own 21% of Clinuvel Pharmaceuticals Limited (ASX:CUV) shares but retail investors control 59% of the company

Is Clinuvel Pharmaceuticals Limited's (ASX:CUV) Stock's Recent Performance Being Led By Its Attractive Financial Prospects?

Photomedicine Pioneer CLINUVEL Unveils Clinical, Cosmetic Ambitions to German Investors

Performance Overview